NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D

被引：0
|
作者：
Aleman, Soo [1 ]
Liu, Yang [2 ]
Xu, Simin [2 ]
Chang, Silvia [2 ]
Martin, Ross [2 ]
Aeschbacher, Thomas [2 ]
May, Lindsey [2 ]
Manhas, Savrina [2 ]
Han, Dong [2 ]
Yazdi, Tahmineh [2 ]
Martinez, Clarissa [2 ]
Ho, Pui Yan [2 ]
Richards, Christopher [2 ]
Marceau, Caleb [2 ]
Manuilov, Dmitry [2 ]
Flaherty, John F. [2 ]
Maiorova, Evguenia [2 ]
Mo, Hongmei [2 ]
Wedemeyer, Heiner [3 ]
Lampertico, Pietro [4 ]
机构：
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden
[2] Gilead Sci Inc, Foster City, CA 94404 USA
[3] Hannover Med Sch, Hannover, Germany
[4] Univ Milan, Dept Pathophysiol & Transplantat, CRC AM & A Migliavacca Ctr Liver Dis, Milan, Italy
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1237-C
引用
收藏
页码：S398 / S399
页数：2
相关论文
共 50 条
  • [21] Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D
    Buti, Maria
    Calleja, Jose Luis
    Rodriguez, Miguel angel
    Dominguez-hernandez, Raquel
    Cantero, Helena
    Espinoza-camac, Nataly
    Casado, Miguel Angel
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2025, 48 (03):
  • [22] Bulevirtide for Chronic Hepatitis D reply
    Wedemeyer, Heiner
    Lampertico, Pietro
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (13): : 1248 - 1248
  • [23] No Resistance to Tenofovir Alafenamide Detected through 144 Weeks of Treatment in Patients with Chronic Hepatitis B
    Chan, Henry Lik Yuen
    Marcellin, Patrick
    Pan, Calvin Q.
    Cathcart, Andrea
    Bhardwaj, Neeru
    Liu, Yang
    Parhy, Bandita
    Zhou, Eric
    Hsieh, David
    Chang, Silvia
    Martin, Ross
    Feierbach, Becket
    Mo, Hongmei
    Gaggar, Anuj
    Flaherty, John F.
    Shalimar
    Izumi, Namiki
    Lim, Young-Suk
    HEPATOLOGY, 2018, 68 : 231A - 231A
  • [24] No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients with Chronic Hepatitis B
    Chan, Henry Lik-Yuen
    Fung, Scott
    Cathcart, Andrea L.
    Liu, Yang
    Ku, Karin S.
    Flaherty, John F.
    Miller, Michael D.
    Gaggar, Anuj
    Kitrinos, Kathryn M.
    Lim, Young-Suk
    Buti, Maria
    HEPATOLOGY, 2016, 64 : 909A - 909A
  • [25] Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana
    Berger, Annemarie
    Ciesek, Sandra
    Manuilov, Dmitry
    Mercier, Renee-Claude
    Da, Ben L.
    Chee, Grace M.
    Li, Mingyang
    Flaherty, John F.
    Lau, Audrey H.
    Osinusi, Anu
    Wiesch, Julian Schulze zur
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2024, 81 (04)
  • [26] Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease
    Sapuk, Ayaz
    Steinhoff, Leonie
    Huenninghaus, Kristin
    Willuweit, Katharina
    Alavijeh, Jassin Rashidi
    Hild, Benedikt
    Asar, Lucia
    Schmidt, Hartmut H.
    Schramm, Christoph
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 2024
  • [27] BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH NON-COMPENSATED LIVER CIRRHOSIS DUE TO HEPATITIS D
    Barsukova, Natalia Alexandrovna
    Bogomolov, Pavel
    Buyeverov, Alexey O.
    Koblov, Sergei
    Isaeva, Ekaterina
    Kalashnikov, Michail Vladislavovich
    Shub, Nadezhda Anatolyevna
    Arapova, Maria Valeryevna
    HEPATOLOGY, 2023, 78 : S2142 - S2142
  • [28] Efficacy and safety of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta at 96 weeks: Results from an interim analysis of a phase 3 randomized study
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana
    Manuilov, Dmitry
    Mercier, Renee-Claude
    An, Qi
    Freismuth, Aurelie
    Flaherty, John F.
    Osinusi, Anu
    Lau, Audrey
    Wiesch, Julian Schulze Zur
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 101 - 102
  • [29] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
    Wedemeyer, Heiner
    Aleman, Soo
    Brunetto, Maurizia
    Blank, Antje
    Andreone, Pietro
    Bogomolov, Pavel
    Chulanov, Vladimir
    Mamonova, Nina
    Geyvandova, Natalia
    Morozov, Viacheslav
    Sagalova, Olga
    Stepanova, Tatyana
    Manuilov, Dmitry
    Mercier, Renee-Claude
    An, Qi
    Flaherty, John
    Osinusi, Anu
    Lau, Audrey
    zur Wiesch, Julian Schulze
    Cornberg, Markus
    Zeuzem, Stefan
    Lampertico, Pietro
    GUT, 2023, 72 (SUPPL_3) : A103 - A104
  • [30] No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) or TDF plus Emtricitabine (FTC/TDF) Combination Therapy Through 96 Weeks in Chronic Hepatitis B (CHB) Patients with Documented Resistance to Lamivudine (LAM)
    Corsa, Amoreena C.
    Liu, Yang
    Mitchell, Ben C.
    Flaherty, John F.
    Miller, Michael D.
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2012, 56 : 382A - 383A
12345